| Literature DB >> 35252757 |
Richard M Mariita1, Amy C Wilson Miller1, Rajul V Randive1.
Abstract
Human norovirus (HuNoV) is a highly contagious pathogenic virus that is transmitted through contaminated food, water, high-touch surfaces and aerosols. Globally, there are an estimated 685 million infections annually due to norovirus, including 200 million affecting children under the age of 5. HuNoV causes approximately 50, 000 child deaths per year and costs an estimated USD $60 billion annually in healthcare. This study sought to determine the inactivation profile of ultraviolet subtype C (UVC) against norovirus using a UVC light-emitting diode (LED) array, KL265-50V-SM-WD. The array emitted radiation at 269 nm peak wavelength and a measured fluence of 1.25 mW cm-2 at a 7 cm source-surface distance. Since the HuNoV is not cultivable, the study utilized feline calicivirus (FCV) ATCC VR-782, a recommended surrogate as challenge organism. The test followed modified ASTM E2197. Assessment of virus inactivation was performed using a plaque assay method. With irradiance at a UVC dose of 22.5 mJ cm-2, the study obtained 99.9 % virus reduction (3 log reduction). The results demonstrate that the UVC LED array can provide effective inactivation of HuNoV.Entities:
Keywords: Caliciviridae; UVC; feline calicivirus; inactivation; norovirus; surrogate
Year: 2022 PMID: 35252757 PMCID: PMC8895607 DOI: 10.1099/acmi.0.000323
Source DB: PubMed Journal: Access Microbiol ISSN: 2516-8290
Fig. 1.(a) The UVC array was driven at 350 mA during the norovirus inactivation study. (b) The array had two fans and a heat sink for thermal management and was tested at 7 cm height.
Inactivation performance of an array (KL265-50V-SM-WD) emitting UVC radiation at 269 nm peak wavelength with intensity of 1.25 mW cm−2 revealed no inactivation differences at 18 and 22 s of irradiation. A dose of 22.5 mJ cm−2 was enough to obtain a >3 log reduction. All experiments were performed in duplicate (intra-experimental repeats) and means were used for inactivation efficacy determination
|
Exposure time (s) |
Dose (mJ cm−2) |
Average viral burden (p.f.u./disc) |
Average log viral burden (p.f.u./disc) |
Log reduction compared to control (0 s) |
Percentage reduction |
|---|---|---|---|---|---|
|
Zero (control) |
0.0 |
4.00+05 |
5.60 |
|
|
|
12 |
15.0 |
8.00+02 |
2.90 |
2.70 |
99.80 |
|
18 |
22.5 |
1.50+02 |
2.18 |
3.43 |
99.96 |
|
22 |
27.5 |
2.00+02 |
2.30 |
3.30 |
99.95 |
na, not applicable.